Isomorphic Labs — IsoDDE Engine and First Human Trials
IsoDDE 50% vs AlphaFold-3 23.3% on hard protein-ligand cases; 17 programs; Phase 1 by end-2026; $2.1B Series B
Isomorphic Labs — IsoDDE + Human Trials
Provenance note: Source host returned HTTP 403; this file is summary-derived from discovery-search extraction, corroborated across multiple 2026 reports. Underlying primary = Isomorphic's IsoDDE technical report (2026-02-10).
Core Developments
- IsoDDE (Isomorphic Drug Design Engine), technical report 2026-02-10: on the hardest protein-ligand structure-prediction cases, IsoDDE achieved 50% accuracy vs AlphaFold 3's 23.3% — more than double the system that underpinned the 2024 Nobel-recognized work.
- 17 active programs across oncology, immunology, cardiovascular.
- First AI-designed drugs to enter Phase 1 by end of 2026 (incl. first AI-designed cancer drug).
- Funding: $2.1B Series B (Thrive Capital–led).
Industry Context (lens: platform-vs-asset)
Isomorphic is the platform-thesis flagship (engine first, assets second). Caveat from the broader field: AI drug discovery drew more capital in 2024–2026 than any biotech subsector since immuno-oncology, yet has zero approved drugs to date — the platform→asset bridge is still unproven. Recursion's Boltz-2 (with MIT) approaches FEP accuracy ~1,000× faster, illustrating the speed claims; Recursion has spent >$1B over a decade without a commercial drug.
Source: Isomorphic Labs to Begin Human Trials (fetch blocked; summary-derived). Primary: Isomorphic IsoDDE technical report, 2026-02-10.